Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras

Area of Science:

• Neurology
• Mitochondrial Biology
• Muscle Disorders

Background:

• Sporadic inclusion body myositis (IBM) is the most prevalent late-onset myopathy.
• Its pathogenesis involves degenerative, inflammatory, and mitochondrial factors, with unclear interrelations.
• Mitochondrial dysregulation is a key, yet not fully understood, aspect of IBM.

Purpose of the Study:

• To explore mitochondrial dysregulation in IBM muscle.
• To compare these alterations with other muscle disorders.
• To evaluate the potential of targeting mitochondria therapeutically for IBM.

Main Methods:

• Review of histological and serum biomarkers for mitochondrial alterations in IBM.
• Analysis of mitochondrial dynamics, including fusion and mitophagy.
• Examination of mitochondrial DNA (mtDNA) integrity and content.
• Assessment of oxidative phosphorylation defects and associated molecular changes.

Main Results:

• IBM muscle exhibits disturbed mitochondrial dynamics, abnormal mitophagy, and increased mitochondrial content.
• Evidence of mitochondrial DNA alterations and mild depletion is present.
• Defects in oxidative phosphorylation, particularly Complex IV, are observed.
• Perturbations in mitokines and regulatory RNAs indicate broader mitochondrial dysfunction.

Conclusions:

• Mitochondrial abnormalities are significant contributors to IBM pathogenesis.
• IBM should be considered a mitochondrial disease.
• Targeting mitochondrial dysfunction presents a promising therapeutic avenue for IBM.